Moreover, it was also considered the use of SGLT2-Is for CV risk reduction in T2DM patients with non-diabetic CKD (eGFR ≥ 25 mL/min/1.73 m2 or urinary albumin creatinine ≥ 300 mg/g) [113]. Here, SLC5A2 is linked to chronic kidney disease.